Dyn.
Internet performance company
- Reports this week
- 0
- Active events
- 0
- Connections
- 33
What's happening
Earlier this month
Gone quiet
No new reports in 90+ days-
Dyn announced an offering pursuant to SEC registration, with Morgan Stanley and Raymond James serving as joint book-running managers, and Jones leading the effort.Some support1 report
-
Both Dyn and Viking Therapeutics are noted as competing firms within the clinical-stage biotech sector.Some support1 report
-
Dyne Therapeutics is expanding and strengthening its board, appointing Greene, while John Cox serves as CEO.Some support1 report
-
Dyne announced the development of therapies for DMD and myotonic dystrophy type 1, with John Cox serving as CEO.Some support3 reports1 development inside
-
Dyne received FDA Breakthrough Therapy Designation and submitted revised protocols based on feedback regarding its therapies for DMD and myotonic dystrophy type 1.Speculative1 report
-
JonesTrading initiated coverage with a Buy rating for Dyn on June 26, 2025.Some support2 reports
-
Dyn filed an offering with the SEC on July 3, 2025, with Morgan Stanley and Stifel serving as joint book-running managers.Speculative3 reports1 development inside
-
Dyn secured debt financing from Hercules Capital on July 1, 2025.Speculative1 report
-
Wildon R Farwell joined Satellos Bioscience Inc. as CMO and will advance SAT-3247 in trials.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Dyn this week
News at the entities that move Dyn most-
FDA StructuralFDA conducted widespread seizures of prohibited food items and products across Pune, Nashik, Mumbai, Konkan, and Nanded.Moves Dyn
-
SEC StructuralWedbush Securities Inc. purchased a new stake in the Capital Group Municipal Income ETF, filing a disclosure with the SEC.Moves Dyn
-
Jefferies Financial Group Mentioned togetherJefferies Financial Group initiated coverage on Moody's shares, and Morgan Stanley subsequently raised its price target for the company.Moves Dyn
-
Viking Therapeutics OperationalMajor pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.Moves Dyn
-
Jones StructuralJones' legacy inspired a new scholarship endowment at Austin Peay State University.Moves Dyn
-
board of directors StructuralRoselle was elected to the Board of Directors on October 24, 2026.Moves Dyn
Connections
The 15 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Dyn is subject to formal regulatory review and designation processes by the FDA for its therapeutics.
-
John Cox Structural
John Cox holds the role of President and CEO of Dyn Therapeutics.
-
DMD Structural
Dyn is actively developing therapeutic treatments targeting DMD.
-
SEC Structural
Dyn is subject to SEC regulation, requiring disclosure of transactions.
-
Jason Rhodes Structural
Jason Rhodes serves as a director of Dyn, a formal governance role that binds the individual to the company's operations.
-
Viking Therapeutics Operational
The firms actively compete within the clinical-stage biotech sector.
-
Morgan Stanley Transactional
Morgan Stanley is engaged as a joint book-running manager for Dyn, indicating a specific, time-bound financial service arrangement.
-
Jones Structural
Jones holds the functional role of lead manager for Dyn.
Show all 15 connections
-
board of directors Structural
The board of directors operates as a formal governing body within the structure of Dyn.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group issued a buy rating on the shares of Dyn.
-
Stifel Transactional
Stifel acted as a joint book-running manager in a financial offering involving Dyn.
-
Nasdaq Shared context
Dyn operates as a company listed and trading on the Nasdaq stock exchange.
-
Raymond James Operational
Raymond James is serving as a joint book-running manager for Dyn.
-
Donald Trump Shared context
Dyn is explicitly noted as not being affected by the tariffs associated with Donald Trump's policies.
-
Jones Mentioned together
No evidence linking Dyn and Jones was found in the provided snapshots.
History
Events by the month they beganJune 2026
9 events- Trump-era tariffs are reportedly benefiting certain AI stocks, coinciding with the spin-off of Millrose Properties, Inc. from Lennar Corporation.
- Both Dyn and Viking Therapeutics are noted as competing firms within the clinical-stage biotech sector.
- Dyne Therapeutics is expanding and strengthening its board, appointing Greene, while John Cox serves as CEO.
- Dyne announced the development of therapies for DMD and myotonic dystrophy type 1, with John Cox serving as CEO.
- Dyne received FDA Breakthrough Therapy Designation and submitted revised protocols based on feedback regarding its therapies for DMD and myotonic dystrophy type 1.
- JonesTrading initiated coverage with a Buy rating for Dyn on June 26, 2025.
- Dyn filed an offering with the SEC on July 3, 2025, with Morgan Stanley and Stifel serving as joint book-running managers.
- Dyn secured debt financing from Hercules Capital on July 1, 2025.
- Wildon R Farwell joined Satellos Bioscience Inc. as CMO and will advance SAT-3247 in trials.